



November 11, 2019

BY ELECTRONIC DELIVERY

Vermont Attorney General's Office  
109 State Street  
Montpelier, VT 05609  
[AGO.highcostprescriptiondrugs@vermont.gov](mailto:AGO.highcostprescriptiondrugs@vermont.gov)

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Celgene is providing notice of the introduction of a new prescription drug with a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program:

- REBLOZYL<sup>®</sup> (luspatercept-aamt) [59572-0711-01]
- REBLOZYL<sup>®</sup> (luspatercept-aamt) [59572-0775-01]

Sincerely,

A handwritten signature in blue ink that reads 'James Kilgallon'.

James Kilgallon  
Executive Director, Pricing and Contracting Strategy